Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
Is there any contraindication for a patient receiving omalizumab for treatment of her lung aspergillosis to receive adjuvant breast radiotherapy?
Related Questions
Is DCISionRT appropriate for multifocal DCIS?
How do you approach breast hypofractionation RNI with the results of the Skagen Trial 1?
Would you offer partial breast radiation to a young breast cancer patient with BRCA 1 if all other criteria are met?
Which patient subgroups do you plan to omit regional nodal irradiation for, given the publication of NSABP B-51?
Given the 10-year outcomes of UK FAST-Forward presented at ESTRO, how have you expanded the use of ultra-hypofractionation in your practice?
How would you approach surveillance imaging for men with early-stage, hormone receptor-positive breast cancer after unilateral mastectomy?
In a patient with T2N0 breast cancer with skin involvement s/p lumpectomy and negative margins, if you are offering whole breast radiation, would you bolus your tangent fields?
Is it appropriate to use bolus with hypofractionated PMRT?
How are you clinically incorporating the data presented from RT Charm at ASTRO 2024?
In which patients do you utilize a breast MRI as part of the initial workup for breast cancer?
